FRUZAQLA (fruquintinib), FDA Approved for the Treatment of Metastatic Colorectal Cancer, Available at Biologics by McKesson

CARY, N.C., Nov. 15, 2023 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Takeda as a specialty pharmacy provider for FRUZAQLATM (fruquintinib). FRUZAQLA, approved by the U.S. Food and Drug Administration (FDA) on Nov. 8, 2023, is ...
Source: McKesson News - Category: Information Technology Source Type: news